📢 Due to the high demand for innovations in drug screening, LumiSTAR Biotechnology (Taiwan), HCS Pharma (France), and Molecular Device (USA) co-organized a symposium at BIO Asia-Taiwan 2023 this year, focusing on cutting-edge technologies for high-throughput phenotypic screening.
✨ Date: 2023/7/27 Thu. Time: 13:30~17:00
✨ Agenda:
| Time | Event/Presentation |
|---|---|
13:30~14:00 | Registration |
14:00~14:10 | Opening Remarks and Group Photo |
| 14:10~14:50 | Transforming drug discovery: Leverage the power of LumiRDT™ with advanced human iPSC technology and high-throughput screening Yu-Fen Chang, PhD CEO, LumiSTAR Biotechnology, Inc. (Taiwan) |
| 14:50~15:30 | BIOMIMESYS® Hydroscaffold, a ready-to-use organ-specific extracellular matrix for relevant phenotypic screening Nathalie Maubon, PhD CEO & CSO, HCS Pharma (France) |
| 15:30~16:10 | Overcoming the barriers to 3D organoid adoption: A complete workflow to enable largescale production of organoids and their use in automated high-throughput applications Angeline Lim, PhD Senior Applications Scientist, Molecular Device (USA) |
| 16:10~16:15 | Closing Remarks |
| 16:15~17:00 | Refreshment and Networking |
✨ Organizer:
